Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
ADAMTS13
Biomarkers
HAIC
Hepatocellular carcinoma
Vascular endothelial growth factor
Von Willebrand factor
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Dec 2020
07 Dec 2020
Historique:
received:
04
08
2020
revised:
09
10
2020
accepted:
13
11
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Prediction of HAIC treatment response is important for improving the prognosis in patients with hepatocellular carcinoma (HCC). The progression of HCC is related to hypercoagulability and angiogenesis. It is known that ADAMTS13 and von Willebrand factor (VWF) are related to hypercoagulability. In addition, previous study reported that the association between ADAMTS13 and VWF, and angiogenesis To investigate whether ADAMTS13 and VWF become useful biomarkers of treatment response in HCC patients before the initiation of HAIC treatment. Seventy-two patients were enrolled in this study. ADAMTS13 activity (ADAMTS13:AC), VWF antigen (VWF:Ag) and VEGF levels were determined ADAMTS13:AC levels in HCC patients with stable disease (SD) + partial response (PR) of HAIC treatment were significantly higher than those with progressive disease (PD) ( VWF:Ag/ADAMTS13:AC ratio may become a useful biomarker of treatment response in HCC patients before the initiation of HAIC treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Prediction of HAIC treatment response is important for improving the prognosis in patients with hepatocellular carcinoma (HCC). The progression of HCC is related to hypercoagulability and angiogenesis. It is known that ADAMTS13 and von Willebrand factor (VWF) are related to hypercoagulability. In addition, previous study reported that the association between ADAMTS13 and VWF, and angiogenesis
AIM
OBJECTIVE
To investigate whether ADAMTS13 and VWF become useful biomarkers of treatment response in HCC patients before the initiation of HAIC treatment.
METHODS
METHODS
Seventy-two patients were enrolled in this study. ADAMTS13 activity (ADAMTS13:AC), VWF antigen (VWF:Ag) and VEGF levels were determined
RESULTS
RESULTS
ADAMTS13:AC levels in HCC patients with stable disease (SD) + partial response (PR) of HAIC treatment were significantly higher than those with progressive disease (PD) (
CONCLUSION
CONCLUSIONS
VWF:Ag/ADAMTS13:AC ratio may become a useful biomarker of treatment response in HCC patients before the initiation of HAIC treatment.
Identifiants
pubmed: 33362379
doi: 10.3748/wjg.v26.i45.7232
pmc: PMC7723670
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
von Willebrand Factor
0
ADAMTS13 Protein
EC 3.4.24.87
ADAMTS13 protein, human
EC 3.4.24.87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7232-7241Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Références
World J Gastrointest Oncol. 2019 May 15;11(5):424-435
pubmed: 31139312
Clin Mol Hepatol. 2019 Dec;25(4):381-389
pubmed: 31405269
Liver Cancer. 2014 Oct;3(3-4):458-68
pubmed: 26280007
Cell Mol Life Sci. 2015 Jan;72(2):349-56
pubmed: 24950743
Hepatology. 2004 Jun;39(6):1517-24
pubmed: 15185292
J Thromb Haemost. 2016 Feb;14(2):306-15
pubmed: 26589836
Hepatology. 2017 Nov;66(5):1556-1569
pubmed: 28617992
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Pathophysiol Haemost Thromb. 2005;34(1):35-40
pubmed: 16293984
Hepatol Res. 2018 Feb;48(3):E52-E60
pubmed: 28628948
Blood. 2005 Aug 1;106(3):922-4
pubmed: 15855280
N Engl J Med. 1998 Nov 26;339(22):1578-84
pubmed: 9828245
J Gastrointest Oncol. 2018 Aug;9(4):741-749
pubmed: 30151271
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Biomed Rep. 2017 Sep;7(3):277-285
pubmed: 28894574
Blood. 2011 Jan 20;117(3):1071-80
pubmed: 21048155
Cancer Res. 1992 Jun 15;52(12):3267-72
pubmed: 1596884
Anticancer Res. 2015 Apr;35(4):2205-10
pubmed: 25862879
Semin Thromb Hemost. 2008 Nov;34(8):734-41
pubmed: 19214911
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72
pubmed: 22753481
Thromb Res. 2018 Mar;163:138-145
pubmed: 29407626
Blood. 2017 Jul 6;130(1):1-2
pubmed: 28684444
J Thromb Haemost. 2012 Dec;10(12):2428-37
pubmed: 23020315
Hepatol Res. 2012 May;42(5):459-72
pubmed: 22292786
J Gastroenterol. 2012 Jun;47(6):686-95
pubmed: 22382631
United European Gastroenterol J. 2018 Nov;6(9):1401-1409
pubmed: 30386613
J Clin Invest. 1986 Dec;78(6):1456-61
pubmed: 3491092
BMC Gastroenterol. 2019 Oct 21;19(1):167
pubmed: 31638892
J Clin Lab Anal. 2018 Jan;32(1):
pubmed: 28374895
Transfusion. 2006 Aug;46(8):1444-52
pubmed: 16934083
Gut Liver. 2016 May 23;10(3):332-9
pubmed: 27114433